NASDAQ$ALXO
ALX Oncology Holdings Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter and provided an update on the Company’s portfolio of clinical programs in development.
ALX Oncology reported its Q2 2023 financial results, highlighting the advancement of the ASPEN-06 trial and a strategic shift towards combinations with anti-cancer antibodies, ADCs, and PD-1/PD-L1 inhibitors. The company is terminating the ASPEN-02 and ASPEN-05 programs, reallocating resources to ongoing programs.
- Advanced Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423.
- Terminated azacitidine combination development programs: ASPEN-02 in MDS and ASPEN-05 in AML.
- Focusing on combinations with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune checkpoint inhibitors.
- Received Orphan Drug Designation from the European Commission for evorpacept for the treatment of patients with gastric cancer.
Headline financials
Revenue & EPS history
ALX Oncology · Revenue · Quarterly
$0
Forward guidance
ALX Oncology anticipates several milestones, including an update from the ASPEN-06 trial in the second half of 2023 and expansion of the ADC platform by Q4 2023.
Tailwinds
- Update of data from ASPEN-06 trial in the second half of 2023.
- Expansion of the ADC platform to identify clinical development candidates by the fourth quarter of 2023.
Headwinds
- IND filing for ALTA-002 delayed to the first quarter of 2024 due to CMC-related issues.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.7%
Avg return
30 days after
59%
13 / 22 earnings
Positive
+26.0%
Q4 2024
Best reaction
-21.9%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -10.2% | -6.8% | -13.2% | |
| Q3 2025 | +15.5% | +8.5% | +20.3% | |
| Q2 2025 | +7.4% | +57.9% | +72.4% | |
| Q1 2025 | -8.2% | -0.2% | +25.9% | |
| Q4 2024 | +26.0% | -6.4% | -50.4% | |
| Q3 2024 | -5.2% | -12.4% | +5.9% | |
| Q1 2024 | -2.4% | -8.7% | -45.8% | |
| Q4 2023 | +3.0% | -16.2% | -17.2% | |
| Q3 2023 | +13.2% | +21.8% | +70.5% | |
| Q2 2023 | +1.4% | -2.6% | -1.4% | |
| Q1 2023 | +0.6% | -7.0% | +23.3% | |
| Q4 2022 | -13.6% | -15.9% | -28.7% | |
| Q3 2022 | -1.8% | +1.1% | -14.2% | |
| Q2 2022 | +2.6% | +26.6% | +5.6% | |
| Q1 2022 | -6.8% | -8.1% | -24.1% | |
| Q4 2021 | +7.7% | -1.3% | +2.7% | |
| Q3 2021 | +8.8% | +6.3% | -26.4% | |
| Q2 2021 | +0.6% | +2.1% | +16.6% | |
| Q1 2021 | -1.1% | -1.6% | +7.3% | |
| Q4 2020 | -21.9% | -19.4% | -24.8% | |
| Q3 2020 | +4.2% | +34.6% | +65.1% | |
| Q2 2020 | +2.0% | -3.8% | -10.0% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro